Dimitrios Skaltsas, CEO & Co-Founder of Intelligencia AI: $15.5 Million Raised to Build the Future of Drug Development

Early Challenges and Inspiration: Dimitrios shared how he transitioned from McKinsey to co-founding Intelligencia AI, inspired by his work on big data and AI in pharmaceutical R&D.

First Customer Success: Landing their first major pharmaceutical client was a pivotal moment, achieved through relentless networking and demonstrating their AI's potential to transform drug development.

Impact of COVID-19: The pandemic accelerated the pharmaceutical industry's adoption of AI, highlighting the need for faster and more efficient drug development processes.

Explaining AI in Pharma: Intelligencia AI stands out by focusing on explainability, providing users with transparent, data-driven insights that enhance decision-making rather than relying on opaque black-box models.

Navigating the AI Hype: Dimitrios discussed how the rise of AI has brought both opportunity and noise, emphasizing the importance of high-quality data and a clear understanding of AI’s practical applications in pharma.

Future Vision: Intelligencia AI aims to become the gold standard in drug development risk assessment, expanding its therapeutic coverage and geographic reach, particularly into Asia.